Incyte (INCY)
(Delayed Data from NSDQ)
$65.87 USD
+0.50 (0.76%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $65.87 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Incyte (INCY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$70.44 | $86.00 | $48.00 | 7.76% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for Incyte comes to $70.44. The forecasts range from a low of $48.00 to a high of $86.00. The average price target represents an increase of 7.76% from the last closing price of $65.37.
Analyst Price Targets (18)
Broker Rating
Incyte currently has an average brokerage recommendation (ABR) of 2.24 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 2.14 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, nine are Strong Buy, representing 42.86% of all recommendations. A month ago, Strong Buy represented 42.86%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/INCY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 11 | 11 | 12 | 12 | 11 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 0 | 0 | 0 |
ABR | 2.24 | 2.24 | 2.14 | 2.14 | 2.10 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | Not Identified | Not Identified | Hold | Hold |
7/2/2024 | BMO Capital Markets | Evan Seigerman | Hold | Strong Sell |
5/1/2024 | Goldman Sachs | Salveen Richter | Hold | Hold |
5/1/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
4/30/2024 | Wells Fargo Securities | Derek C Archila | Hold | Hold |
4/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/23/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Not Available | Hold |
4/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
3/12/2024 | Not Identified | Not Identified | Hold | Hold |
2/23/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/14/2024 | JMP Securities | Reni Benjamin | Strong Buy | Hold |
2/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/6/2024 | William Blair | Matt Phipps | Strong Buy | Strong Buy |
12/13/2023 | SVB Securities | Andrew Berens | Hold | Strong Buy |
12/4/2023 | Guggenheim Securities | Michael Schmidt | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.24 |
ABR (Last week) | 2.24 |
# of Recs in ABR | 21 |
Average Target Price | $70.50 |
LT Growth Rate | 13.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | 1.16 |